Markers of activation of platelets and neutrophils in PV or ET patients: relationship with treatment
| . | Controls . | PV and ET patients . | ||||
|---|---|---|---|---|---|---|
| No previous thrombosis . | Previous thrombosis . | |||||
| ASA yes HU no . | ASA yes HU yes . | All ASA yes HU yes . | Arterial ASA yes HU yes . | Venous ASA yes HU yes . | ||
| N | 70 | 25 | 35 | 21 | 14 | 7 |
| Median age, yr (range) | 65 (36-89) | 57 (46-89) | 64 (36-87) | 67 (41-88) | 66 (41-88) | 67 (62-83 |
| White blood cells, ×109/L | 6.2 ± 0.7 | 9.2 ± 0.9* | 7.1 ± 0.4*† | 7.3 ± 0.5 | 7.0 ± 0.6 | 7.8 ± 0.9*† |
| Granulocytes, ×109/L | 3.5 ± 0.3 | 6.8 ± 0.7* | 5.1 ± 0.4*† | 5.4 ± 0.4 | 5.1 ± 0.4 | 5.9 ± 0.9*† |
| Platelets, ×109/L | 223.1 ± 20.5 | 581.0 ± 79.1* | 387.1 ± 41.3*† | 452.1 ± 58.7* | 535.5 ± 75.4* | 327.0 ± 54.2*†‡ |
| Platelets expressing P-selectin | 6.8 ± 0.8 | 21.6 ± 2.3* | 22.6 ± 2.3* | 29.0 ± 3.2*†‡ | 28.3 ± 3.8*†‡ | 30.3 ± 6.1*†‡ |
| Platelets expressing tissue factor | 3.9 ± 0.8 | 20.3 ± 2.9* | 22.8 ± 4.2* | 36.9 ± 6.3*†‡ | 38.6 ± 6.9*†‡ | 31.1 ± 8.8*†‡ |
| Platelets with bound fibrinogen | 3.1 ± 0.6 | 24.2 ± 3.8* | 30.0 ± 2.7* | 44.2 ± 4.1*†‡ | 46.0 ± 4.0*†‡ | 39.3 ± 11.7*† |
| Neutrophil MPO content | 159.9 ± 8.4 | 88.6 ± 9.8* | 123.1 ± 8.2*† | 55.1 ± 3.4*†‡ | 55.3 ± 2.9*†‡ | 54.9 ± 3.0*†‡ |
| Neutrophils with bound fibrinogen | 3.1 ± 0.8 | 18.4 ± 3.7* | 20.5 ± 4.1* | 43.8 ± 4.8*†‡ | 40.4 ± 7.1*†‡ | 48.1 ± 6.1*†‡ |
| Neutrophils expressing tissue factor | 2.9 ± 0.6 | 22.8 ± 3.0* | 14.1 ± 2.1*† | 29.1 ± 4.8*‡ | 29.6 ± 6.1*†‡ | 28.1 ± 8.3*‡ |
| Monocytes with bound fibrinogen | 2.1 ± 0.4 | 18.9 ± 3.7* | 20.2 ± 4.7* | 28.6 ± 3.8*† | 30.9 ± 6.1*†‡ | 25.5 ± 4.2* |
| Monocytes expressing tissue factor | 2.4 ± 0.4 | 20.1 ± 3.6* | 17.6 ± 3.0* | 23.9 ± 4.3* | 25.5 ± 5.5*‡ | 20.6 ± 7.7* |
| Platelet-neutrophil aggregates | 6.8 ± 0.5 | 18.6 ± 1.7* | 11.8 ± 1.1*† | 29.5 ± 3.5*†‡ | 25.7 ± 3.3*†‡ | 37.0 ± 7.6*†‡ |
| Platelet-monocyte aggregates | 5.1 ± 0.9 | 20.4 ± 2.5* | 11.0 ± 1.1*† | 17.1 ± 2.7*† | 14.7 ± 3.0* | 21.9 ± 5.3*‡ |
| Neutrophils with intracellular platelets | 2.2 ± 0.4 | 48.4 ± 3.1* | 47.8 ± 3.4* | 13.6 ± 2.3*†‡ | 14.3 ± 3.0*† | 12.0 ± 3.8*†‡ |
| Monocytes with intracellular platelets | 0.9 ± 0.2 | 42.4 ± 4.9* | 36.1 ± 4.1* | 15.1 ± 3.6*†‡ | 16.4 ± 4.7*†‡ | 12.4 ± 5.4*†‡ |
| . | Controls . | PV and ET patients . | ||||
|---|---|---|---|---|---|---|
| No previous thrombosis . | Previous thrombosis . | |||||
| ASA yes HU no . | ASA yes HU yes . | All ASA yes HU yes . | Arterial ASA yes HU yes . | Venous ASA yes HU yes . | ||
| N | 70 | 25 | 35 | 21 | 14 | 7 |
| Median age, yr (range) | 65 (36-89) | 57 (46-89) | 64 (36-87) | 67 (41-88) | 66 (41-88) | 67 (62-83 |
| White blood cells, ×109/L | 6.2 ± 0.7 | 9.2 ± 0.9* | 7.1 ± 0.4*† | 7.3 ± 0.5 | 7.0 ± 0.6 | 7.8 ± 0.9*† |
| Granulocytes, ×109/L | 3.5 ± 0.3 | 6.8 ± 0.7* | 5.1 ± 0.4*† | 5.4 ± 0.4 | 5.1 ± 0.4 | 5.9 ± 0.9*† |
| Platelets, ×109/L | 223.1 ± 20.5 | 581.0 ± 79.1* | 387.1 ± 41.3*† | 452.1 ± 58.7* | 535.5 ± 75.4* | 327.0 ± 54.2*†‡ |
| Platelets expressing P-selectin | 6.8 ± 0.8 | 21.6 ± 2.3* | 22.6 ± 2.3* | 29.0 ± 3.2*†‡ | 28.3 ± 3.8*†‡ | 30.3 ± 6.1*†‡ |
| Platelets expressing tissue factor | 3.9 ± 0.8 | 20.3 ± 2.9* | 22.8 ± 4.2* | 36.9 ± 6.3*†‡ | 38.6 ± 6.9*†‡ | 31.1 ± 8.8*†‡ |
| Platelets with bound fibrinogen | 3.1 ± 0.6 | 24.2 ± 3.8* | 30.0 ± 2.7* | 44.2 ± 4.1*†‡ | 46.0 ± 4.0*†‡ | 39.3 ± 11.7*† |
| Neutrophil MPO content | 159.9 ± 8.4 | 88.6 ± 9.8* | 123.1 ± 8.2*† | 55.1 ± 3.4*†‡ | 55.3 ± 2.9*†‡ | 54.9 ± 3.0*†‡ |
| Neutrophils with bound fibrinogen | 3.1 ± 0.8 | 18.4 ± 3.7* | 20.5 ± 4.1* | 43.8 ± 4.8*†‡ | 40.4 ± 7.1*†‡ | 48.1 ± 6.1*†‡ |
| Neutrophils expressing tissue factor | 2.9 ± 0.6 | 22.8 ± 3.0* | 14.1 ± 2.1*† | 29.1 ± 4.8*‡ | 29.6 ± 6.1*†‡ | 28.1 ± 8.3*‡ |
| Monocytes with bound fibrinogen | 2.1 ± 0.4 | 18.9 ± 3.7* | 20.2 ± 4.7* | 28.6 ± 3.8*† | 30.9 ± 6.1*†‡ | 25.5 ± 4.2* |
| Monocytes expressing tissue factor | 2.4 ± 0.4 | 20.1 ± 3.6* | 17.6 ± 3.0* | 23.9 ± 4.3* | 25.5 ± 5.5*‡ | 20.6 ± 7.7* |
| Platelet-neutrophil aggregates | 6.8 ± 0.5 | 18.6 ± 1.7* | 11.8 ± 1.1*† | 29.5 ± 3.5*†‡ | 25.7 ± 3.3*†‡ | 37.0 ± 7.6*†‡ |
| Platelet-monocyte aggregates | 5.1 ± 0.9 | 20.4 ± 2.5* | 11.0 ± 1.1*† | 17.1 ± 2.7*† | 14.7 ± 3.0* | 21.9 ± 5.3*‡ |
| Neutrophils with intracellular platelets | 2.2 ± 0.4 | 48.4 ± 3.1* | 47.8 ± 3.4* | 13.6 ± 2.3*†‡ | 14.3 ± 3.0*† | 12.0 ± 3.8*†‡ |
| Monocytes with intracellular platelets | 0.9 ± 0.2 | 42.4 ± 4.9* | 36.1 ± 4.1* | 15.1 ± 3.6*†‡ | 16.4 ± 4.7*†‡ | 12.4 ± 5.4*†‡ |
Results are expressed as mean ± SEM of the percentage of CD61+ platelets expressing P-selectin, tissue factor, and fibrinogen; mean ± SEM arbitrary units of myeloperoxidase (MPO) fluorescence within CD66b+ neutrophils; mean ± SEM of the percentage of CD66b+ neutrophils that express tissue factor or fibrinogen, that form heterotypic aggregates with platelets, or that contain intracellular platelets; or mean ± SEM of the percentage of CD14+ monocytes that express tissue factor or fibrinogen, that form heterotypic aggregates with platelets, or that contain intracellular platelets.
ASA indicates acetylsalicylic acid; and HU, hydroxyurea.
Statistically different from controls, P < .05.
Statistically different from patients not treated with HU, P < .05.
Statistically different from patients without previous thrombosis treated with HU, P < .05.